The Food and Drug Administration recommended that COVID-19 vaccine producers should include recent versions of the Omicron coronavirus variant in booster injections.
According to the agency, booster injections should include the original strain of the virus, which is in existing vaccines, and both the BA.4 and BA.5 lineages of the Omicron variety. These lineages now make up most of the viral strains circulating in the country. They are even more efficient at evading the immune system than some earlier iterations of the virus and are highly contagious.
Manufacturers of Pfizer, Moderna, and Novavax have already begun testing Omicron-targeted variations of their products, with preliminary results showing that they stimulate the immune response to the Omicron variety more effectively than current dosages. may be able to.
The BA.1 lineage of the omicron version, an older variation, is present in the versions they are testing. The FDA said in a statement that the companies should conduct additional clinical trials on BA.4 and BA.5 injections, but continue to collect data from BA.1 shots.
Current COVID-19 vaccinations continue to provide excellent protection against serious illness and death, but the combination of decreased immunity and new variations has made people less resistant to infection. According to experts, the next generation of vaccines should provide more durable immunity to the disease.
Read also: Kovid-19 cases are increasing continuously in the capital of Odisha